Our Pipeline
Character is committed to pioneering precision medicine solutions for polygenic diseases. Our growing therapeutic pipeline is focused on developing groundbreaking treatments aimed at addressing diseases with significant unmet medical needs. Our research teams are rapidly advancing preclinical programs with a primary focus on dry Age-Related Macular Degeneration (AMD) and Primary Open-Angle Glaucoma (POAG).
CTX203
High risk intermediate AMD
Phase 1
CTX203 is a potential first-in-class lipid-modulating agent designed to prevent irreversible retinal cell death and vision loss. Based on human genetics evidence, CTX203 is a de novo designed peptide.
Character has also developed a proprietary lipid pathway-specific polygenic risk score to identify patients more likely to progress quickly and to respond to lipid-modulating therapy.
CTX114
Geographic Atrophy
IND-Enabling
CTX114 is a novel complement inhibitor designed to slow down the rate of retinal cell death and vision loss. Based on human genetics evidence, CTX114 is designed for enhanced protection of retinal surfaces from complement activation. Character Bio has generated a compelling preclinical data package demonstrating CTX114’s potential best-in-class approach to complement inhibition.
Character has also developed a proprietary complement pathway- specific polygenic risk score to identify patients more likely to progress quickly and to respond to complement-directed therapy.
AMD
Undisclosed
RESEARCH
POAG
Undisclosed
RESEARCH